Homology modelling of human CYP1A2 based on the CYP2C5 crystallographic template structure

References

• ANZENBACHER, P. and ANZENBACHEROVA, E., 2001, Cytochromes P450 and metabolism of xenobiotics. Cellular and Molecular Life Sciences, 58, 737–747.
   PubMed Web of Science ®Google Scholar
• BAUER, C., OSMAN, A. M., CEREIGNANI, G., GIALLUCA, N. and PAOLINI, M., 2001, A unified theory of enzyme kinetics based upon the systematic analysis of the variations of k Km and km,/Km and the relevant AG values — possible implications in chemotherapy and biotechnology. Biochemical Pharmacology, 61, 1049–1055.
   PubMed Web of Science ®Google Scholar
• BECQUEMONT, L., LEBoT, M. A., RICHE, C., FUNCK-BRENTANO, C., JAILLON, P. and BEAUNE, P., 1998, Use of heterologously expressed human cytochrome P4501A2 to predict tacrine—fiuvoxamine drug interaction in man. Pharmacogenetics, 8, 101–108.
   Google Scholar
• BORN, S. L., CAUDILL, D., FLITER, K. L. and PURDON, M. P., 2002, Identification of the cytochromes P450 that catalyse coumarin 3,4-epoxidation and 3-hydroxylation. Drug Metabolism and Disposition, 30, 483–487.
   PubMed Web of Science ®Google Scholar
• CHING, M. S., BICHARA, N., BLAKE, C. L., GHABRIAL, H., TUKEY, R. H. and SMALLWOOD, R. A., 1996, Propranolol 4- and 5-hydroxylation and N-desisopropylation by cloned human cytochrome P4501A1 and P4501A2. Drug Metabolism and Disposition, 24, 692–694.
   PubMed Web of Science ®Google Scholar
• CLARKE, S. E., AYRTON, A. D. and CHENERY, R. J., 1994, Characterization of the inhibition of P4501A2 by furafylline. Xenobiotica, 24, 517–526.
   PubMed Web of Science ®Google Scholar
• CUPP-VICKERY, J. R. and PouLos, T. L., 1995, Structure of cytochrome P450eryF involved in erythromycin synthesis. Structural Biology, 2, 144–153.
   Google Scholar
• CYRK, T. and STROBEL, H. W., 1998, Photoaffinity labeling of cytochrome P4501A1 with azidocumene: identification of cumene hydroperoxide binding region. Archives of Biochemistry and Biophysics, 349, 95–104.
   PubMed Web of Science ®Google Scholar
• EATON, D. L., GALLAGHER, E. P., BAMMLER, T. K. and KUNZE, K. L., 1995, Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics, 5, 259–274.
   PubMedGoogle Scholar
• ELKS, J. and GANELLIN, C. R., 1990, Dictionary of Drugs (London: Chapman & Hall).
   Google Scholar
• FACCIOLA, G., HIDESTRAND, M., VON BAHR, C. and TYBRIN G., 2001, Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes. European Journal of Clinical Pharmacology, 56, 881–888.
   PubMed Web of Science ®Google Scholar
• FUHR, U., STROBL, G., MANAUT, F., ANDERS, E.-M., SORGEL, F., LOPEZ-DE-BRINAS, E., CHU, D. T. W., PERNET, A. G., MAHR, G., SANZ, F. and STAIB, A. H., 1993, Quinoline antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. Molecular Pharmacology, 43, 191–199.
   Google Scholar
• FURUYA, H., SHIMIZU, T., HATANO, M. and FUJII-KURIYAMA, Y., 1989a, Mutations at the distal and proximal sites of cytochrome P450d changed regio-specificity of acetanilide hydroxylations. Biochemical and Biophysical Research Communications, 160, 669–676.
   Google Scholar
• FURUYA, H., SHimizu, T., HIRANO, K., HATANO, M., FUJII-KURIYAMA, Y., RAAG, R. and PouLos, T. L., 1989b, Site-directed mutagenesis of rat liver cytochrome P450d: catalytic activities toward benzphetamine and 7-ethoxycoumarin. Biochemistry, 28, 6848–6857.
   PubMed Web of Science ®Google Scholar
• GALLAGHER, E. P., KUNZE, K. L., STAPLETON, P. L. and EATON, D. L., 1996, The kinetics of afiatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P4501A2 and 3A4. Toxicology and Applied Pharmacology, 141, 595–606.
   PubMed Web of Science ®Google Scholar
• GOTOH, 0., 1992, Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. Journal of Biological Chemistry, 267, 83–90.
   Google Scholar
• HADJOKAS, N. E., DAI, R., FRIEDMAN, F. K., SPENCE, M. J., VESTAL, R. E., CUSACK, B. J. and MA, Y 2002, Arginine to lysine 108 substitution in recombinant CYP1A2 abolishes methoxy-resorufin metabolism in lymphoblastoid cells. British Journal of Pharmacology, 136, 345–352.
   Google Scholar
• HAMMONS, G. J., MILTON, D., STEPPS, K., GUENGERICH, F. P., TUKEY, R. H. and KADLUBAR, F. F., 1997, Metabolism of carcinogenic heterocyclic and aromatic amines by recombinant human cytochrome P450 enzymes. Carcinogenesis, 18, 851–854.
   PubMed Web of Science ®Google Scholar
• HANSCH, C. and LEO, A. J., 1979, Substituent Constants for Correlation Analysis in Chemistry and Biology (New York: Wiley).
   Google Scholar
• HORN, E. P., TUCKER, M. A., LAMBERT, G., SILVERMAN, D., ZAMETKIN, D., SINHA, R., HARTGE, T., LANDI, M. T. and CAPRASO, N. E., 1995, A study of gender-based cytochrome P4501A2 variability: a possible mechanism for the male excess of bladder cancer. Cancer Epidemiology, Biomarkers and Prevention, 4, 529–533.
   PubMed Web of Science ®Google Scholar
• JOSEPHY, P. D., BIBEAU, K. L. and EVANS, D. H., 2000, Activation of MeIQ (2-amino-3,4-dimethylimidazo-[4,5-Aquinoline) by sequence variants of recombinant human cytochrome P4501A2. Environmental and Molecular Mutagenesis, 35, 328–335.
   PubMed Web of Science ®Google Scholar
• KAWAHRI, K., WATANABE, J. and HAYASHI, S.-I., 1992, Roles in genetic polymorphisms of drug metabolizing enzymes in humans. Journal of Basic Clinical Physiology and Pharmacology, 3, 76–77.
   Google Scholar
• KERLAN, V., DREANO, Y., BERCOVICI, J. P., BEAUNE, P. H., FLOCH, H. H. and BERTHOU, F., 1992, Nature of cytochromes P450 involved in the 2-/4-hydroxylations of estradiol in human liver microsomes. Biochemical Pharmacology, 44, 1745–1756.
   PubMed Web of Science ®Google Scholar
• KRAINEV, A. G., SHimizu, T., HIROYA, K. and HATANO, M., 1992, Effects of mutations at Lys250, Arg251 and Lys253 of cytochrome P4501A2 on the catalytic activities and the bindings of bifunctional axial ligands. Archives of Biochemistry and Biophysics, 298, 198–203.
   PubMed Web of Science ®Google Scholar
• KUNZE, K. L. and TRAGER, W. F., 1993, Isoform-selective mechanism-based inhibition of human cytochrome P4501A2 by furafylline. Chemical Research in Toxicology, 6, 649–656.
   PubMed Web of Science ®Google Scholar
• LAINE, R., URBAN, P. and POMPON, D., 1994, Segment directed mutagenesis of human cytochrome P4501A2 by PCR and effect on the catalytic activity and substrate selectivity. In M. C. Lechner (ed.), Cytochrome P450 (Paris: Libbey), pp. 451–453.
   Google Scholar
• LEWIS, D. F. V., 2001, Guide to Cytochrome P450 Structure and Function (London: Taylor & Francis). LEWIS, D. F. V., 2002, Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure. Xenobiotica, 32, 305–323.
   Google Scholar
• LEWIS, D. F. V. and DICKINS, M., 2002, Baseline lipophilicity relationships in human cytochromes P450 associated with drug metabolism. Drug Metabolism Reviews (in press).
   Google Scholar
• LEWIS, D. F. V. and LAKE, B. G., 1996, Molecular modelling of CYP1A subfamily members based on an alignment with CYP102: rationalization of CYP1A substrate specificity in terms of active site amino acid residues. Xenobiotica, 26, 723–753.
   Google Scholar
• LEWIS, D. F. V., LAKE, B. G., GEORGE, S. G., DICKINS, M., EDDERSHAW, P. J., TARBIT, M. H., BERESFORD, A. P., GOLDFARB, P. S. and GUENGERICH, F. P., 1999, Molecular modelling of CYP1 family enzymes CYP1A1, CYP1A2, CYP1A6 and CYP1B1 based on sequence homology with CYP102. Toxicology, 139, 53–79.
   Google Scholar
• LEWIS, D. F. V., MODI, S. and DICKINS, M., 2001, Quantitative structure-activity relationships (QSARs) within substrates of human cytochromes P450 involved in drug metabolism. Drug Metabolism and Drug Interactions, 18, 221–242.
   Google Scholar
• LEWIS, D. F. V., MODI, S. and DICKINS, M., 2002, Structure-activity relationships for human cytochrome P450 substrates and inhibitors. Drug Metabolism Reviews, 34, 69–82.
   Google Scholar
• Li, H. and PouLos, T. L., 1997, The structure of the cytochrome P450Bm3 haem domain complexed with the fatty acid substrate, palmitoleic acid. Nature Structural Biology, 4, 140–146.
   PubMedGoogle Scholar
• LOZANO, J. J., LOPEZ-DE BRINAS, E., CENTENO, N. B., GUIGO, R. and SANZ, F., 1997, Three-dimensional modelling of human cytochrome P4501A2 and its interaction with caffeine and MeIQ. Journal of Computer-Aided Molecular Design, 11, 395–408.
   Google Scholar
• NEWTON, D. W. and KLUZA, R. B., 1978, plC values of medicinal compounds in pharmacy practice. Drug Intelligence and Clinical Pharmacy, 12, 546–554.
   Google Scholar
• PARIKH, A., JOSEPHY, P. D. and GUENGERICH, F. P., 1999, Selection and characterization of human cytochrome P 4501A2 mutants with altered catalytic properties. Biochemistry, 38, 5283–5289. PELKONEN, 0., MAENPAA, J., TAAVITSAINEN, P., RAUTIO, A. and RAUNIO, H., 1998, Inhibition and induction of human cytochromes P405 (CYP) enzymes. Xenobiotica, 28, 1203-1253.
   Google Scholar
• PouLos, T. L., FINZELL, B. C. and HOWARD, A. J., 1987, High-resolution crystal structure of cytochrome P450e.,,. Journal of Molecular Biology, 195, 687–700.
   PubMed Web of Science ®Google Scholar
• RENDIC, S. and DICARLO, F. J., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metabolism Reviews, 29, 413–580.
   PubMed Web of Science ®Google Scholar
• RODRIGUES, A. D., 1999, Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochemical Pharmacology, 57, 465–480.
   PubMed Web of Science ®Google Scholar
• SANGSTER, J., 1989, Octanol-water partition coefficients of simple organic compounds. Journal of Physical and Chemical Reference Data, 18, 1111–1189.
   Web of Science ®Google Scholar
• SESARDIC, D., BOOBIS, A. R., MURRAY, B. P., MURRAY, S., SEGURA, J., DE LA TORRE, R. and DAVIES, D. S., 1990, Furafylline is a potent and selective inhibitor of cytochrome P4501A2 in man. British Journal of Clinical Pharmacology, 29, 651–663.
   PubMed Web of Science ®Google Scholar
• SHEN, S. and STROBEL, H. W., 1992, The role of cytochrome P450 lysine residues in the interaction between cytochrome P4501A1 and NADPH-cytochrome P450 reductase. Archives of Biochemistry and Biophysics, 294, 83–90.
   PubMed Web of Science ®Google Scholar
• SHimizu, T., ITo, 0., HANATO, M. and FUJII-KURIYAMA, Y., 1991, CO binding studies of engineered cytochrome P450d: effects of mutations at putative distal sites in the presence of polycyclic hydrocarbons. Biochemistry, 30, 4659–4662.
   Google Scholar
• SHimizu, T., MURAKAMI, Y. and HATANO, M., 1994, Glu318 and Thr319 mutations of cytochrome P4501A2 remarkably enhance homolytic 0-0 cleavage of alkyl hydroperoxides. Journal of Biological Chemistry, 269, 13296–13304.
   PubMed Web of Science ®Google Scholar
• SuzuKi, T. and KUDO, Y., 1990, Automatic log P estimation based on combined additive modeling methods. Journal of Computer-Aided Molecular Design, 4, 155–198.
   PubMed Web of Science ®Google Scholar
• TASSANEEYAKUL, W., BIRKETT, D. J. McMANus, M. E., TASSANNEYAKUL, W., VERONESE, M. E., ANDERSSON, T., TUKEY, R. H. and MINERS, J. 0., 1994, Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochemical Pharmacology, 47, 1767–1776.
   Google Scholar
• TASSANEEYAKUL, W., BIRKETT, D. J., VERONESE, M. E., McMANus, M. E., TUKEY, R. H., QUATTROCHI, L. C., GELBOIN, H. V. and MINERS, J. 0., 1993, Specificity of substrate and inhibitor probes for human cytochromes P4501A1 and 1A2. Journal of Pharmacology and Experimental Therapeutics, 265, 401–407.
   Google Scholar
• TASSANEEYAKUL, W., MOHAMED, Z., BIRKETT, D. J., McMANus, M. E., VERONESE, M. E., TUKEY, R. H., QUATTROCHI, L. C., GONZALEZ, F. J. and MINERS, J. 0., 1992, Caffeine as a probe for human cytochromes P450: validation using cDNA expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics, 2, 173–183.
   Google Scholar
• TURESKY, R. J., CONSTABLE, A., RICHOZ, J., VARGA, N., MARKOVIC, J., MARTIN, M. V. and GUENGERICH, F. P., 1998, Activation of heterocyclic aromatic amines by rat and human liver microsomes and by purified rat and human cytochrome P4501A2. Chemical Research in Toxicology, 11, 925–936.
   PubMed Web of Science ®Google Scholar
• UENG, Y.-F., JAN, W.-C., LIN, L.-C., CHEN, T.-L., GUENGERICH, F. P. and CHEN, C.-F., 2002, The alkaloid rutaecarpine is a selective inhibitor on cytochrome P450 1A in mouse and human liver microsomes. Drug Metabolism and Disposition, 30, 349–353.
   PubMed Web of Science ®Google Scholar
• WILLIAMS, P. A., COSME, J., SRIDHAR, V., JOHNSON, E. F. and McREE, D. E., 2000, Mammalian cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Molecular Cell, 5, 121–131.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, H., SHAW, P. M., GUENGERICH, F. P. and SHIMADA, T., 1998, Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. Chemical Research in Toxicology, 11, 659–665.
   PubMed Web of Science ®Google Scholar
• ZHAI, S. DAI, R., FRIEDMAN, F. K. and VESTAL, R. E., 1998, Comparative inhibition of human cytochromes P4501A1 and 1A2 by fiavonoids. Drug Metabolism and Disposition, 26, 989–992.
   Google Scholar
• ZHAO, K., MURRAY, S., DAVIES, D. S., BOOBIS, A. R. and GOODERHAM, N. J., 1994, Metabolism of the food derived mutagen and carcinogen 2-amino-l-methyl-6-phenylimidazo(4,5-b) pyridine (PhIP) by human liver microsomes. Carcinogenesis, 15, 1285–1288.
   PubMed Web of Science ®Google Scholar